Immuneering Corp (IMRX)
Healthcare
Biotechnology
4.20 $
+1.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Immuneering Corp (IMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -45 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -4.4 | -15 | -31 | -44 | -49 | -55 | -45 | |
| 0.0 | 0.1 | 0.2 | 0.8 | 0.4 | 0.4 | 0.7 | |
| 0.6 | 1.1 | 1.8 | 4.1 | 5.7 | 6.5 | 6.3 | |
| 2.8 | 1.1 | 1.5 | 4.1 | – | – | – | |
| 0.4 | 1.3 | 0.9 | 1.7 | -1.0 | -0.9 | 3.8 | |
| 0.0 | 0.1 | 0.1 | 0.7 | 0.3 | 0.1 | 0.1 | |
| 0.0 | -0.1 | -76 | 42 | 7.3 | 26 | -89 | |
| – | – | 144 | 0.0 | – | – | – | |
| 3.8 | – | – | – | – | – | – | |
| 17 | 38 | 144 | 0.0 | 28 | 5.3 | 227 | |
| 13 | 23 | 38 | -2.3 | -13 | -23 | 93 | |
| -4.5 | -15 | -31 | -45 | -49 | -55 | -45 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.